AbbVie Q3 adjusted EPS $3.82 vs $1.86 year-ago, beats $3.74 estimate

The headline beat is less telling than the guidance raise: lifting the full-year adjusted EPS floor by roughly twenty cents signals management sees the quarter's momentum as durable rather than a one-off. That matters for anyone tracking large-cap pharma earnings quality, since the year-ago comparison is flattered by a low base and the revenue beat itself was narrow. The open question is whether the raised range holds through the remaining quarter, or whether the thin top-line cushion leaves the guidance exposed to any softness.